-
1
-
-
84893772728
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
-
Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 492-509
-
-
Smolen, J.S.1
Landewé, R.2
Breedveld, F.C.3
-
2
-
-
0037103310
-
De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo
-
Dervieux T, Brenner TL, Hon YY, et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood 2002;100:1240-7.
-
(2002)
Blood
, vol.100
, pp. 1240-1247
-
-
Dervieux, T.1
Brenner, T.L.2
Hon, Y.Y.3
-
3
-
-
0032518281
-
Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5-nucleotidase-mediated conversion of adenine nucleotides
-
Morabito L, Montesinos MC, Schreibman DM, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998;101:295-300.
-
(1998)
J Clin Invest
, vol.101
, pp. 295-300
-
-
Morabito, L.1
Montesinos, M.C.2
Schreibman, D.M.3
-
4
-
-
0027139914
-
The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation
-
Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.
-
(1993)
J Clin Invest
, vol.92
, pp. 2675-2682
-
-
Cronstein, B.N.1
Naime, D.2
Ostad, E.3
-
5
-
-
0031661580
-
The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis
-
Godfrey C, Sweeney K, Miller K, et al. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 1998;46:369-76.
-
(1998)
Br J Clin Pharmacol
, vol.46
, pp. 369-376
-
-
Godfrey, C.1
Sweeney, K.2
Miller, K.3
-
6
-
-
20444389821
-
Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis
-
Hiraga Y, Yuhki Y, Itoh K, et al. Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis. Mod Rheumatol 2004;14:135-42.
-
(2004)
Mod Rheumatol
, vol.14
, pp. 135-142
-
-
Hiraga, Y.1
Yuhki, Y.2
Itoh, K.3
-
7
-
-
0027989630
-
Intraindividual variability of the bioavailability of low-dose methotrexate after oral administration in rheumatoid arthritis
-
Lebbe C, Beyeler C, Gerber NJ, et al. Intraindividual variability of the bioavailability of low-dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994;53:475-7.
-
(1994)
Ann Rheum Dis
, vol.53
, pp. 475-477
-
-
Lebbe, C.1
Beyeler, C.2
Gerber, N.J.3
-
8
-
-
0027753061
-
Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis
-
Ravelli A, Di Fuccia G, Molinaro M, et al. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J Rheumatol 1993;20:1573-7.
-
(1993)
J Rheumatol
, vol.20
, pp. 1573-1577
-
-
Ravelli, A.1
Di Fuccia, G.2
Molinaro, M.3
-
9
-
-
54049158589
-
MTX correlate to plasma concentrations and clinical efficacy
-
Hornung N, Ellingsen T, Attermann J, et al. MTX correlate to plasma concentrations and clinical efficacy. J Rheumatol 2008;35:1709-15.
-
(2008)
J Rheumatol
, vol.35
, pp. 1709-1715
-
-
Hornung, N.1
Ellingsen, T.2
Attermann, J.3
-
10
-
-
55849140884
-
Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis
-
Dalrymple JM, Stamp LK, O'Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008;58:3299-308.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 3299-3308
-
-
Dalrymple, J.M.1
Stamp, L.K.2
O'Donnell, J.L.3
-
11
-
-
0029898079
-
Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis
-
Bannwarth B, Pehourcq F, Schaeverbeke T, et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996;30:194-210.
-
(1996)
Clin Pharmacokinet
, vol.30
, pp. 194-210
-
-
Bannwarth, B.1
Pehourcq, F.2
Schaeverbeke, T.3
-
12
-
-
54049158589
-
Patients with rheumatoid arthritis treated with methotrexate (MTX): Concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy
-
Hornung N, Ellingsen T, Attermann J, et al. Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy. J Rheumatol 2008;35:1709-15.
-
(2008)
J Rheumatol
, vol.35
, pp. 1709-1715
-
-
Hornung, N.1
Ellingsen, T.2
Attermann, J.3
-
13
-
-
0033023168
-
Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis
-
Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999;17:313-20.
-
(1999)
Clin Exp Rheumatol
, vol.17
, pp. 313-320
-
-
Angelis-Stoforidis, P.1
Vajda, F.J.2
Christophidis, N.3
-
14
-
-
23444443994
-
Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: Results of a multicentred cross sectional observational study
-
Dervieux T, Furst D, Lein DO, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005;64:1180-5.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 1180-1185
-
-
Dervieux, T.1
Furst, D.2
Lein, D.O.3
-
15
-
-
84863751959
-
A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate
-
Hobl EL, Jilma B, Erlacher L, et al. A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate. Clin Exp Rheumatol 2012;30:156-63.
-
(2012)
Clin Exp Rheumatol
, vol.30
, pp. 156-163
-
-
Hobl, E.L.1
Jilma, B.2
Erlacher, L.3
-
16
-
-
84921311336
-
Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis
-
de Rotte MC, den Boer E, de Jong PH, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis 2015;74:408-14.
-
(2015)
Ann Rheum Dis
, vol.74
, pp. 408-414
-
-
De Rotte, M.C.1
Den Boer, E.2
De Jong, P.H.3
-
17
-
-
84921320976
-
Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients
-
Calasan MB, den Boer E, de Rotte MC, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Ann Rheum Dis 2015;74:402-7.
-
(2015)
Ann Rheum Dis
, vol.74
, pp. 402-407
-
-
Calasan, M.B.1
Den Boer, E.2
De Rotte, M.C.3
-
18
-
-
77956055481
-
2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/ European League Against Rheumatism collaborative initiative
-
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 2569-2581
-
-
Aletaha, D.1
Neogi, T.2
Silman, A.J.3
-
19
-
-
0030068817
-
Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American college of rheumatology and the world health organization/international league against rheumatism criteria
-
van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
-
(1996)
Arthritis Rheum
, vol.39
, pp. 34-40
-
-
Van Gestel, A.M.1
Prevoo, M.L.2
Van 'T Hof, M.A.3
-
20
-
-
0027420099
-
Development of a disease activity score based on judgment in clinical practice by rheumatologists
-
van der Heijde DM, van 't Hof M, van Riel PL, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
-
(1993)
J Rheumatol
, vol.20
, pp. 579-581
-
-
Van Der Heijde, D.M.1
Van 'T Hof, M.2
Van Riel, P.L.3
-
21
-
-
0141838977
-
HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis
-
Dervieux T, Orentas LD, Marcelletti J, et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 2003;49:1632-41.
-
(2003)
Clin Chem
, vol.49
, pp. 1632-1641
-
-
Dervieux, T.1
Orentas, L.D.2
Marcelletti, J.3
-
22
-
-
84979081127
-
Prediction of the therapeutic response to methotrexate at 24 weeks by methotrexatepolyglutamates concentration in erythrocytes at 8 weeks in patients with rheumatoid arthritis
-
[Epub ahead of print 20 Jul 2016]
-
Murosaki T, Nagatani K, Sato T, et al. Prediction of the therapeutic response to methotrexate at 24 weeks by methotrexatepolyglutamates concentration in erythrocytes at 8 weeks in patients with rheumatoid arthritis. Mod Rheumatol 2016. [Epub ahead of print 20 Jul 2016]. doi: 10.1080/14397595.2016.1208137
-
(2016)
Mod Rheumatol
-
-
Murosaki, T.1
Nagatani, K.2
Sato, T.3
-
23
-
-
78549273383
-
Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis
-
Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology (Oxford) 2010;49:2337-45.
-
(2010)
Rheumatology (Oxford)
, vol.49
, pp. 2337-2345
-
-
Dervieux, T.1
Zablocki, R.2
Kremer, J.3
-
24
-
-
75749135305
-
Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy
-
Stamp LK, O'Donnell JL, Chapman PT, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 2010;62:359-68.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 359-368
-
-
Stamp, L.K.1
O'Donnell, J.L.2
Chapman, P.T.3
-
25
-
-
78650793942
-
The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response
-
Becker ML, Gaedigk R, van Haandel L, et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum 2011;63:276-85.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 276-285
-
-
Becker, M.L.1
Gaedigk, R.2
Van Haandel, L.3
-
26
-
-
34848925807
-
Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease
-
Brooks AJ, Begg EJ, Zhang M, et al. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit 2007;29:619-25.
-
(2007)
Ther Drug Monit
, vol.29
, pp. 619-625
-
-
Brooks, A.J.1
Begg, E.J.2
Zhang, M.3
-
27
-
-
84954360828
-
The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression
-
Atsumi T, Yamamoto K, Takeuchi T, et al. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis 2016;75:75-83.
-
(2016)
Ann Rheum Dis
, vol.75
, pp. 75-83
-
-
Atsumi, T.1
Yamamoto, K.2
Takeuchi, T.3
-
28
-
-
44949192753
-
An update on methotrexate pharmacogenetics in rheumatoid arthritis
-
Ranganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 2008;9:439-51.
-
(2008)
Pharmacogenomics
, vol.9
, pp. 439-451
-
-
Ranganathan, P.1
-
29
-
-
84923260875
-
Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis
-
den Boer E, de Rotte MC, Pluijm SM, et al. Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis. J Rheumatol 2014;41:2167-78.
-
(2014)
J Rheumatol
, vol.41
, pp. 2167-2178
-
-
Den Boer, E.1
De Rotte, M.C.2
Pluijm, S.M.3
-
30
-
-
41849115973
-
Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis
-
Ranganathan P, Culverhouse R, Marsh S, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008;35:572-9.
-
(2008)
J Rheumatol
, vol.35
, pp. 572-579
-
-
Ranganathan, P.1
Culverhouse, R.2
Marsh, S.3
|